creativebiolabs's blog

On March 8, 2023, Nature released a new paper titled "Macrophage fumarate hydratase restrains mtRNA-mediated interferon production." Researchers from Trinity College Dublin in Ireland and the University of Cambridge in the United Kingdom have achieved a crucial breakthrough in understanding how the body changes throughout the development of inflammatory disorders, identifying a possible new therapeutic target in the process.

While there is evidence that messenger RNA (mRNA) vaccines are effective against viral infections, there is less information about the efficacy of this platform against bacterial pathogens. New research, "A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium," was published in the peer-reviewed international journal Science Advances. Researchers at Tel Aviv University and other Israeli institutions claimed to have created the first mRNA vaccine with the potential to be 100% effective against a bacterium that is lethal to humans.

An important monoamine neurotransmitter is serotonin, also known as 5-hydroxytryptamine (5-HT). Serotonin regulates appetite and nutrition in a variety of animal species. Historically, a number of pharmaceuticals were marketed to control body weight by increasing serotonin levels in the central nervous system, but they were subsequently withdrawn due to a variety of severe adverse effects. This is likely owing to the diversity of serotonergic neurons involved in the regulation of numerous physiological functions.

Researchers from the University of Texas Southwestern Medical Center note in a new study that cell membrane protrusions called follicles (blebs) normally signal the end of life for healthy cells, but the opposite is true for melanoma cells, which activate these protrusions to help them survive and spread. These findings may lead to new therapies for melanoma and other malignancies. The results were published online on 1 March 2023 in the journal Nature in an article titled "Blebs promote cell survival by assembling oncogenic signalling hubs."

The pharmaceutical giant Pfizer Inc., the industry-leading creator of anti-cancer drugs, has reached an agreement to purchase Seagen, one of the pioneers in the field of antibody-drug conjugates (ADCs) at the biotech business based outside of Seattle for $43 billion in cash.